The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation

Journal of Biological Chemistry

Volumn 290, Issue 9, 2015, Pages 5462-5469

  Silva, John Paul ^a,b   Vetterlein, Olivia ^a   Jose, Joby ^a   Peters, Shirley ^b   Kirby, Hishani ^a  

^a UCB Celltech   (United Kingdom)

^b UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AFFINITY CHROMATOGRAPHY; AMINO ACIDS; MOLECULES; PHYSIOLOGY;

ANTI-INFLAMMATORY ACTIVITY; BIOLOGICAL MECHANISMS; HUMAN IMMUNOGLOBULIN G; IN-VITRO; NOVEL METHODOLOGY; REDOX CONDITION; THERAPEUTIC EFFICACY; WILD TYPES;

ANTIBODIES;

IMMUNOGLOBULIN G4; INTERLEUKIN 6 ANTIBODY; PROLINE; SERINE; TUMOR NECROSIS FACTOR ALPHA; BISPECIFIC ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ACCURACY; AFFINITY CHROMATOGRAPHY; ANTIBODY ISOLATION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; CALIBRATOR; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; IMMUNOASSAY ANALYZER; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; MUTATION; NORMAL HUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEPLETION; SINGLE AMINO ACID MUTATION; BLOOD; GENETICS; IMMUNOLOGY; MISSENSE MUTATION; WESTERN BLOTTING;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INTERLEUKIN-6; MUTATION, MISSENSE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923802677     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.600973     Document Type: Article

References (35)

1. Salfeld, J. G. (2007) Isotype selection in antibody engineering. Nat. Biotechnol. 25, 1369-1372
2. Natsume, A., In, M., Takamura, H., Nakagawa, T., Shimizu, Y., Kitajima, K., Wakitani, M., Ohta, S., Satoh, M., Shitara, K., and Niwa, R. (2008) Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68, 3863-3872
3. Brüggemann, M., Williams, G. T., Bindon, C. I., Clark, M. R., Walker, M. R., Jefferis, R., Waldmann, H., and Neuberger, M. S. (1987) Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166, 1351-1361
4. Riechmann, L., Clark, M., Waldmann, H., and Winter, G. (1988) Reshaping human antibodies for therapy. Nature 332, 323-327
5. Aalberse, R. C., Stapel, S. O., Schuurman, J., and Rispens, T. (2009) Immunoglobulin G4: an odd antibody. Clin. Exp. Allergy 39, 469-477
6. Angal, S., King, D. J., Bodmer, M. W., Turner, A., Lawson, A. D., Roberts, G., Pedley, B., and Adair, J. R. (1993) A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol. Immunol. 30, 105-108
7. Deng, L., Wylie, D., Tsao, Y. S., Larkin, B., Voloch, M., and Ling, W. L. (2004) Detection and quantification of the human IgG4 half-molecule, HL, from unpurified cell-culture supernatants. Biotechnol. Appl. Biochem. 40, 261-269
8. Labrijn, A. F., Rispens, T., Meesters, J., Rose, R. J., den Bleker, T. H., Loverix, S., van den Bremer, E. T., Neijssen, J., Vink, T., Lasters, I., Aalberse, R. C., Heck, A. J., van de Winkel, J. G., Schuurman, J., and Parren, P. W. (2011) Species-specific determinants in the IgG CH3 domain enable Fabarm exchange by affecting the noncovalent CH3-CH3 interaction strength. J. Immunol. 187, 3238-3246
9. Schuurman, J., Perdok, G. J., Gorter, A. D., and Aalberse, R. C. (2001) The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intrachain disulfide bonds. Mol. Immunol. 38, 1-8
10. Schuurman, J., Van Ree, R., Perdok, G. J., Van Doorn, H. R., Tan, K. Y., and Aalberse, R. C. (1999) Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites. Immunology 97, 693-698
11. Stubenrauch, K., Wessels, U., Regula, J. T., Kettenberger, H., Schleypen, J., and Kohnert, U. (2010) Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys. Drug. Metab. Dispos. 38, 84-91
12. Margni, R. A., and Binaghi, R. A. (1988) Nonprecipitating asymmetric antibodies. Annu. Rev. Immunol. 6, 535-554
13. Burton, D. R., and Wilson, I. A. (2007) Immunology. Square-dancing antibodies. Science 317, 1507-1508
14. Labrijn, A. F., Aalberse, R. C., and Schuurman, J. (2008) When binding is enough: nonactivating antibody formats. Curr. Opin. Immunol. 20, 479-485
15. Labrijn, A. F., Buijsse, A. O., van den Bremer, E. T., Verwilligen, A. Y., Bleeker, W. K., Thorpe, S. J., Killestein, J., Polman, C. H., Aalberse, R. C., Schuurman, J., van de Winkel, J. G., and Parren, P. W. (2009) Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat. Biotechnol. 27, 767-771
16. van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martínez-Martínez, P., Vermeulen, E., den Bleker, T. H., Wiegman, L., Vink, T., Aarden, L. A., De Baets, M. H., van de Winkel, J. G., Aalberse, R. C., and Parren, P. W. (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317, 1554-1557
17. Shapiro, R. I., Plavina, T., Schlain, B. R., Pepinsky, R. B., Garber, E. A., Jarpe, M., Hochman, P. S., Wehner, N. G., Bard, F., Motter, R., Yednock, T. A., and Taylor, F. R. (2011) Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri(R)) with endogenous IgG4. J. Pharm. Biomed. Anal. 55, 168-175
18. Peters, S. J., Smales, C. M., Henry, A. J., Stephens, P. E., West, S., and Humphreys, D. P. (2012) Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability. J. Biol. Chem. 287, 24525-24533
19. Labrijn, A. F., Meesters, J. I., de Goeij, B. E., van den Bremer, E. T., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M. J., van Berkel, P. H., van de Winkel, J. G., Schuurman, J., and Parren, P. W. (2013) Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc. Natl. Acad. Sci. U.S.A. 110, 5145-5150
20. DeSilva, B., Smith, W., Weiner, R., Kelley, M., Smolec, J., Lee, B., Khan, M., Tacey, R., Hill, H., and Celniker, A. (2003) Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20, 1885-1900
21. Viswanathan, C. T., Bansal, S., Booth, B., DeStefano, A. J., Rose, M. J., Sailstad, J., Shah, V. P., Skelly, J. P., Swann, P. G., and Weiner, R. (2007) Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24, 1962-1973
22. th Ed., United States Government Printing Office, Number 165-492
23. Kabat, E. A., Wu, T. T., Gottesman, K. S., and Foeller, C. (1991) Sequences of Proteins of Immunological Interest, 5th. Ed., United States Public Health Service, National Institutes of Health, Number 91-3242
24. Rispens, T., Vennegoor, A., Wolbink, G. J., Polman, C. H., and Killestein, J. (2012) Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult. Scler. 18, 899-901
25. Bloom, J. W., Madanat, M. S., Marriott, D., Wong, T., and Chan, S. Y. (1997) Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci. 6, 407-415
26. Lewis, K. B., Meengs, B., Bondensgaard, K., Chin, L., Hughes, S. D., Kjaer, B., Lund, S., and Wang, L. (2009) Comparison of the ability of wild type and stabilized human IgG(4) to undergo Fab arm exchange with endogenous IgG(4)in vitro and in vivo. Mol. Immunol. 46, 3488-3494
27. Rispens, T., Davies, A. M., Ooijevaar-de Heer, P., Absalah, S., Bende, O., Sutton, B. J., Vidarsson, G., and Aalberse, R. C. (2014) Dynamics of interheavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange. J. Biol. Chem. 289, 6098-6109
28. Rose, R. J., Labrijn, A. F., van den Bremer, E. T., Loverix, S., Lasters, I., van Berkel, P. H., van de Winkel, J. G., Schuurman, J., Parren, P. W., and Heck, A. J. (2011) Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure 19, 1274-1282
29. Wilkinson, I. C., Fowler, S. B., Machiesky, L., Miller, K., Hayes, D. B., Adib, M., Her, C., Borrok, M. J., Tsui, P., Burrell, M., Corkill, D. J., Witt, S., Lowe, D. C., and Webster, C. I. (2013) Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure. MAbs 5, 406-417
30. Jones, D. P., and Liang, Y. (2009) Measuring the poise of thiol/disulfide couples in vivo. Free Radic Biol. Med. 47, 1329-1338
31. Unt, E., Zilmer, K., Mägi, A., Kullisaar, T., Kairane, C., and Zilmer, M. (2008) Homocysteine status in former top-level male athletes: possible effect of physical activity and physical fitness. Scand. J. Med. Sci. Sports 18, 360-366
32. Rispens, T., den Bleker, T. H., and Aalberse, R. C. (2010) Hybrid IgG4/ IgG4 Fc antibodies form upon 'Fab-arm' exchange as demonstrated by SDS-PAGE or size-exclusion chromatography. Mol. Immunol. 47, 1592-1594
33. Divatia, M., Kim, S. A., and Ro, J. Y. (2012) IgG4-related sclerosing disease, an emerging entity: a review of a multi-system disease. Yonsei. Med. J. 53, 15-34
34. Miles, J., and Riches, P. (1994) The determination of IgG subclass concentrations in serum by enzyme-linked immunosorbent assay: establishment of age-related reference ranges for cord blood samples, children aged 5-13 years and adults. Ann. Clin. Biochem. 31, 245-248
35. Rispens, T., Ooijevaar-de Heer, P., Bende, O., and Aalberse, R. C. (2011) Mechanism of immunoglobulin G4 Fab-arm exchange. J. Am. Chem. Soc. 133, 10302-10311